NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine Clinical Trial In Mexico
Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects... (Source: Immune System / Vaccines News From Medical News Today)




